In 2023 the FDA published guidance on rare diseases. The guidance recognises that many rare diseases are serious conditions ...

This approach, while embedded in clinical guidelines and workflow protocols, does not reflect the underlying biology of ...

At this year's American Society of Clinical Oncology’s Annual Meeting, AstraZeneca presented late-breaking data from the DESTINY-Breast09 Phase III trial evaluating first-line treatment in patients ...

Bayer's rivalry with Boehringer Ingelheim in the development of medicines for HER2-mutated non-small cell lung cancer (NSCLC) ...

That's the top-line finding of the latest financing report from the UK BioIndustry Association (BIA), which reveals that ...

Roche has added another phase 3 trial in its programme for Alzheimer's disease candidate trontinemab and will now test the ...

GSK has moved to shore up its R&D pipeline with a strategic-level deal with China's Jiangsu Hengrui Pharma that spans a dozen drug candidates and could be worth up to $12.5 billion.

Lantheus' pipeline-building drive in radiopharma has continued with a $260 million upfront deal to license rights to two oncology candidates from POINT Biopharma. The agreement covers PNT2002, a ...

Armed with new phase 3 data, Bayer has started preparing filings for elinzanetant as a treatment for vasomotor symptoms (VMS) associated with menopause, setting up a challenge to Astellas’ first ...

AbbVie has secured UK marketing authorisation for ELAHERE (mirvetuximab soravtansine), the first antibody-drug conjugate (ADC ...

This month’s executive moves span a diverse range of organisations – from CDMOs and genomics platforms to diagnostics and ...

Pharma’s next big leap won’t come from the lab. It’ll come from outside the lab, where the rules of narrative, attention, and ...